BD launches a new generation of disposable auto-injectors
6 December 2011
BD Medical has launched the BD Physioject disposable
auto-injector. for self-injection of drugs by patients suffering from
chronic diseases, including rheumatoid arthritis, multiple sclerosis,
asthma and osteoporosis.
The BD Physioject auto-injector presents key benefits for
patients such as ease of use and intuitiveness, one-button
activation, 360° view of the drug and injection process, visual
confirmation of the end of injection, and protection of the needle
after injection. The optimised design for delivery of subcutaneous
injections is defined by patient studies to incorporate those
ergonometric features most relevant to self-injection needs.
Claude Dartiguelongue, President, BD Medical — Pharmaceutical
Systems, said: “BD is committed to providing high-quality,
innovative, highly customisable, cost-effective devices designed
specifically to meet chronic disease patients’ needs for safety,
comfort and convenience. With BD Physioject, developed through a
robust, patient-centric design process, we aim to improve drug
efficacy, the patient experience and treatment compliance.” Clinical
trials show that BD Physioject provides safety, efficiency,
acceptance by patients, and improved pain perception versus the same
syringe used by a nurse.
The BD Physioject
BD Physioject can be customised to offer a modified external
design, flexible injection duration, a range of possible
subcutaneous injection depths, and various syringe options (such as
an end-of-dose indicator) for the unique requirements of
pharmaceutical and biotechnology customers.
It also includes a straightforward two-part assembly process that
simplifies production and manufacturing. To further support its
global customers, BD offers deep understanding and expertise of drug
and device combinations through all stages of the development
process, from design through to launch, including global regulatory
BD Physioject is designed for use in combination with the BD
Hypak for Biotech syringe, a state-of-the-art primary container
optimised for use with biologics to provide, among other benefits, a
low level of interaction with such drugs. The complete integrated
system offers a high-quality, reliable solution for the
“We are excited to be introducing a new generation of disposable
auto-injectors with the launch of BD Physioject and we look forward
to collaborating with pharmaceutical and biotechnology companies to
facilitate the development and launch of self-injection devices,
with the common end goal of improving the lives of patients managing
chronic diseases,” Ms. Dartiguelongue adds.
Merck Serono selected Physioject as the platform for RebiDose,
the Rebif pre-filled pen, for the treatment of multiple sclerosis.
Merck Serono announced the approval of RebiDose in Europe and
Australia in October 2010.
Source: Becton Dickinson